

# MARKET REPORT



Global Atopic Dermatitis Therapeutic Market:  
Opportunities Assessments, Epidemiology Forecast,  
Market Dynamics, Pipeline Analytics, Current Market  
Size and Market Forecast 2018-2028

**BioPortfolio**

Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data



**GervanoRA**<sup>®</sup>

*We Assure Quality With Team Work*

# Global Atopic Dermatitis Therapeutic Market: Opportunities Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analytics, Current Market Size and Market Forecast 2018-2028

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

***We look forward to being of service to you.***

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)7887 945155 or **Email:** [bioportfolio97@gmail.com](mailto:bioportfolio97@gmail.com)

# Global Atopic Dermatitis Therapeutic Market: Opportunities Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analytics, Current Market Size and Market Forecast 2018-2028

GervanoRA's Market Estimation report "Global Atopic Dermatitis Therapeutic Market - Opportunities Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analytics, Current Market Size and Market Forecast 2018-2028" analyzed the current and upcoming opportunities in the Atopic Dermatitis area by assessing the drug market, covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Atopic Dermatitis industry. The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Atopic Dermatitis area. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development. The report evaluated the current market scenario by estimating the market value with respect to Atopic Dermatitis Drug Class, Route of Administration and Age Group. Report primarily focuses on the patent analysis of the key marketed and pipeline drugs to provide a brief understanding about the market opportunities in the Atopic Dermatitis competitive environment. We have also prognosticated the Atopic Dermatitis market share in 11 Major Markets to aid our clients with the commercial and economic opportunities in these geographies.

Our comprehensive analysis on the AD drug pipeline identified 133 drug candidates undergoing different stages of development- from Early R&D to Pre-registration stage. Among these, fifteen drug candidates are in the Phase 3 stage of development, a majority i.e. 46 candidates are in Phase 2 stage, twenty drug candidates are in Phase 1 stage of development and a total of 51 molecules are in non clinical stage of development. We have also identified fourteen drug molecules that are inactive with no drug updates from the year 2015 or have been discontinued. Among them four have been discontinued from further development for AD.

The report has covered more than 110 companies worldwide, involved in the development of new therapeutics for treatment of AD. Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the top 15 Emerging companies in the domain and hence deriving the key leader.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)

Estimated Pipeline Drug Approval Timelines

Current and Future Competitive Landscape

Key Company Profiles with SWOT Analysis

Emerging Company Profiles with Opportunity Assessments

Pipeline Drug Descriptions along with Development milestones (Past and Future)

Atopic Dermatitis market in the 11 major markets along with the revenue and share from 2018 to 2028

Therapeutic market segmentation by drug class, route of administration and geography to better understand and study the individual market segment.

For each segment, the current market trends, growth factors, unmet needs and opportunities, along with market size 2017 and forecast 2018-2028

## Additional Details

**Publisher** : Gervano R A  
**Reference** : GERPHME014  
**Number of Pages** : 216  
**Report Format** : PDF  
**Publisher Information** :



GervanoRA Data Services LLP is a premier provider of syndicated research reports, custom research reports, and consulting services, based in Goa. It provides Market Research And Analysis Services to its clients globally.

GDS aims to deliver a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, aerial views of the competitive framework, and future market trends.

At GervanoRA Data Services, we're playing our part to help clients stay ahead of the curve. We collaboratively work with a wide range of organizations to garner valuable key insights.

# Table Of Contents for Global Atopic Dermatitis Therapeutic Market: Opportunities Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analytics, Current Market Size and Market Forecast 2018-2028

- TABLE OF CONTENTS1 INTRODUCTION1.1. REPORT DESCRIPTION1.2. METHODOLOGY1.3. UPCOMING AND OTHER AVAILABLE REPORTS1.4. ABOUT US: GERVANORA DATA SERVICES2 EXECUTIVE SUMMARY2.1. REPORT SUMMARY2.2. MARKET SNAPSHOT, 2017-20282.3. KEY EVENTS IN ATOPIC DERMATITIS COMPETITIVE SPACE2.4. KEY MAJOR FINDINGS2.4.1. DRIVERS2.4.2. RESTRAINTS2.4.3. UNMET NEEDS AND OPPORTUNITIES3 DISEASE OVERVIEW3.1. DISEASE DEFINITION AND SYMPTOMS3.2. DISEASE CAUSE AND DIAGNOSIS3.3. TREATMENT ALGORITHMS AND GUIDELINES3.4. EPIDEMIOLOGY AND DISEASE BURDEN3.5. EPIDEMIOLOGY STUDIES3.5.1. GLOBAL AND HISTORICAL TRENDS3.6. EPIDEMIOLOGY FORECAST3.6.1. FORECAST METHODOLOGY AND ASSUMPTION3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST4 MARKET DYNAMICS4.1. GOVERNMENT REGULATORY DYNAMICS AND IMPACT4.2. PRICING AND REIMBURSEMENT4.3. DEALS (MERGERS/ACQUISITIONS/ COLLABORATIONS)4.3.1 DEAL ANALYTICS BY DEAL TYPE4.3.2. DEAL ANALYTICS BY ANNUAL FREQUENCY4.3.3. DEAL ANALYTICS BY ACTIVE PLAYERS4.4. NEW DRUG APPROVALS (US FDA) SINCE 20104.5. NEW DRUG APPROVAL (EX-US) SINCE 20104.6. PATENT ANALYTICS (EXPIRIES AND GENERICIZATION)4.6.1. PATENT ANALYTICS OF APPROVED PRODUCTS4.6.2. PATENT ANALYTICS OF KEY PIPELINE PRODUCTS5 PIPELINE ANALYTICS AND ESTIMATED APPROVAL TIMELINES5.1. PIPELINE ANALYTICS BY STAGE OF DEVELOPMENT5.1.1. PRE-REGISTRATION MOLECULES5.1.2. PHASE 3 MOLECULES5.1.3. PHASE 2 MOLECULES5.1.4. PHASE 1 MOLECULES5.1.5. PRECLINICAL MOLECULES5.1.6. EARLY R&D MOLECULES5.1.7. DISCONTINUED AND INACTIVE MOLECULES5.2. PIPELINE ANALYTICS BY GEOGRAPHY5.2.1. UNMET NEEDS AND OPPORTUNITIES5.3. PIPELINE ANALYTICS BY ROUTE OF ADMINISTRATION5.3.1. UNMET NEEDS AND OPPORTUNITIES5.4. PIPELINE ANALYTICS BY DRUG CLASS5.4.1. UNMET NEEDS AND OPPORTUNITIES5.5. PIPELINE ANALYTICS BY MECHANISM OF ACTION5.5.1. UNMET NEEDS AND OPPORTUNITIES5.6. ESTIMATED APPROVAL TIMELINE5.6.1. METHODOLOGY5.6.2. ESTIMATED APPROVAL TIMELINES US & EX-US6 GLOBAL ATOPIC DERMATITIS MARKET BY DRUG CLASS6.1. INTRODUCTION6.2. CORTICOSTEROIDS6.3. EMOLLIENTS/MOISTURIZERS6.4. PDE-4 INHIBITOR6.5. CALCINEURIN INHIBITORS6.6. BIOLOGICS6.7. OTHERS7 GLOBAL ATOPIC DERMATITIS THERAPEUTIC MARKET BY ROUTE OF ADMINISTRATION7.1. INTRODUCTION7.2. TOPICAL7.3. ORAL7.4. INJECTABLE8 ATOPIC DERMATITIS MARKET BY METHOD OF DISPENSING8.1. INTRODUCTION8.2. PRESCRIPTION8.3. OTC9 GLOBAL ATOPIC DERMATITIS THERAPEUTIC MARKET BY GEOGRAPHY9.1. INTRODUCTION9.2. US9.3. UK9.4. GERMANY9.5. FRANCE9.6. ITALY9.7. SPAIN9.8. CHINA9.9. JAPAN9.10. INDIA9.11. RUSSIA9.12. BRAZIL9.13. ROW10 OPPORTUNITY ASSESSMENT AND COMPETITIVE BENCH-MARKING10.1. EXTERNAL DEPENDENCIES10.2. PIPELINE PORTFOLIO10.3. EXPECTED MARKET ENTRIES10.4. PATENTS AND EXCLUSIVITY10.5. MARKETING DYNAMICS AND PARTNERING10.6. 10.7. ACHIEVEMENTS OF SPECIAL REGULATORY ALLOWANCESCOMPANY DEVELOPMENTS11 CURRENT AND FUTURE COMPETITIVE LANDSCAPE11.1. ESTABLISHED COMPANIES11.1.1. ESTABLISHED COMPANY PROFILES11.1.1.1. SANOFI11.1.1.2. PFIZER PHARMACEUTICALS11.1.1.3. REGENERON PHARMACEUTICALS INC11.2. EMERGING COMPANIES11.2.1. EMERGING COMPANY PROFILES11.2.1.1. UNION THERAPEUTICS A/S11.2.1.2. ANAPTYSBIO, INC11.2.1.3. ABEOME CORPORATION11.2.1.4. ASANA BIOSCIENCES, LLC11.2.1.5. SPHERIUM BIOMED S.L11.2.1.6. DS BIOPHARMA LIMITED11.2.1.7. RALEXAR THERAPEUTICS INC11.2.1.8. AKAAL PHARMA PTY LTD11.2.1.9. AOBIOME, LLC11.2.1.10. MENLO THERAPEUTICS INC11.2.1.11. BOTANIX PHARMACEUTICALS11.2.1.12. CARA THERAPEUTICS11.2.1.13. KYMAB LIMITED11.2.1.14. MATRISYS BIOSCIENCE11.2.1.15. QURIENT THERAPEUTICS12. ABBREVIATIONS

# List Of Tables in Global Atopic Dermatitis Therapeutic Market: Opportunities Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analytics, Current Market Size and Market Forecast 2018-2028

## LIST OF TABLES

TABLE 01: REPORT HIGHLIGHTS IN NUMERICALS

TABLE 02: ATOPIC DERMATITIS EPIDEMIOLOGY FORECAST OF US POPULATION (ADULTS) 2018-2025, MILLION

TABLE 03: TOP 10 DEALS RANKED BY THE DEAL AMOUNT

TABLE 04: MAJOR LICENSING DEALS IN ATOPIC DERMATITIS THERAPEUTIC AREA

TABLE 05: MAJOR ACQUISITIONS IN ATOPIC DERMATITIS THERAPEUTIC AREA

TABLE 06: MAJOR AGREEMENTS IN ATOPIC DERMATITIS THERAPEUTIC AREA

TABLE 07: MAJOR COLLABORATIONS IN ATOPIC DERMATITIS THERAPEUTIC AREA

TABLE 08: MAJOR FINANCING DEALS IN ATOPIC DERMATITIS THERAPEUTIC AREA

TABLE 09: ATOPIC DERMATITIS DEALS IN 2019

TABLE 10: US FDA APPROVED DRUGS SINCE 2010

TABLE 11: ATOPIC DERMATITIS APPROVED DRUGS (EX-US) SINCE 2010

TABLE 12: DUPIXENT US AND EU PATENTS OVERVIEW

TABLE 13: DUPIXENT PATENT EXPIRATIONS

TABLE 14: THE U.S PATENTS OF DS BIOPHARMA LIMITED

TABLE 15: THE U.S PATENTS OF AKAAL PHARMA PTY LTD.

TABLE 16: THE U.S PATENTS OF AOBIOIME, LLC

TABLE 17: THE U.S PATENTS OF MENLO THERAPEUTICS INC.

TABLE 18: ATOPIC DERMATITIS PHASE 3 MOLECULES

TABLE 19: ATOPIC DERMATITIS PHASE 2 MOLECULES

TABLE 20: ATOPIC DERMATITIS PHASE 1 MOLECULES

TABLE 21: ATOPIC DERMATITIS PRECLINICAL MOLECULES

TABLE 22: ATOPIC DERMATITIS EARLY R&D STAGE MOLECULES

TABLE 23: ATOPIC DERMATITIS INACTIVE AND DISCONTINUED MOLECULES

TABLE 24: ATOPIC DERMATITIS PIPELINE ANALYTICS BY TOPICAL ROA

TABLE 25: ATOPIC DERMATITIS PIPELINE ANALYTICS BY ORAL ROA

TABLE 26: ATOPIC DERMATITIS PIPELINE ANALYTICS BY INJECTABLE ROA

TABLE 27: ATOPIC DERMATITIS PIPELINE ANALYTICS, IMMUNOMODULATORS

TABLE 28: ATOPIC DERMATITIS PIPELINE ANALYTICS, PDE4 INHIBITORS

TABLE 29: ATOPIC DERMATITIS PIPELINE ANALYTICS, ANTI-INFLAMMATORY

TABLE 30: ATOPIC DERMATITIS PIPELINE ANALYTICS, ANTI-MICROBIAL

TABLE 31: ATOPIC DERMATITIS PIPELINE ANALYTICS, JAK INHIBITORS

TABLE 32: ESTIMATED APPROVAL TIMELINES OF KEY ATOPIC DERMATITIS PIPELINE DRUGS

TABLE 33: GLOBAL AD MARKET BY DRUG CLASS, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 34: AVAILABLE TOPICAL AND SYSTEMIC CORTICOSTEROIDS

TABLE 35: GLOBAL CORTICOSTEROIDS MARKET FOR AD BY COUNTRY, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 36: GLOBAL EMOLLIENTS MARKET FOR AD BY COUNTRY, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 37: GLOBAL PDE4 INHIBITOR MARKET FOR AD BY COUNTRY, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 38: GLOBAL CALCINEURIN INHIBITORS MARKET FOR AD BY COUNTRY, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 39: GLOBAL BIOLOGICS MARKET FOR AD BY COUNTRY, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 40: GLOBAL OTHER DRUGS MARKET FOR AD BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 41: GLOBAL AD MARKET FOR ROA BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 42: GLOBAL AD MARKET FOR TOPICAL DRUGS BY COUNTRY, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 43: GLOBAL AD MARKET FOR ORAL DRUGS BY COUNTRY, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 44: GLOBAL AD MARKET FOR INJECTABLE DRUGS BY COUNTRY, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 45: GLOBAL AD MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 46: GLOBAL AD MARKET FOR PRESCRIPTION DRUGS BY COUNTRY, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 47: GLOBAL AD MARKET FOR OTC DRUGS BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 48: GLOBAL AD MARKET BY COUNTRY, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 49: US AD MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 50: US AD MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 51: US AD MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 52: UK AD MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 53: UK AD MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 54: UK AD MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 55: GERMANY AD MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 56: GERMANY AD MARKET FOR ROA BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 57: GERMANY AD MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 58: FRANCE AD MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 59: FRANCE AD MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 60: FRANCE AD MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 61: ITALY AD MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 62: ITALY AD MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 63: ITALY AD MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 64: SPAIN AD MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 65: SPAIN AD MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 66: SPAIN AD MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 67: CHINA AD MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 68: CHINA AD MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 69: CHINA AD MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 70: JAPAN AD MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 71: JAPAN AD MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 72: JAPAN AD MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 73: INDIA AD MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 74: INDIA AD MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)



TABLE 75: INDIA AD MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 76: RUSSIA AD MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 77: RUSSIA AD MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 78: RUSSIA AD MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 79: BRAZIL AD MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 80: BRAZIL AD MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 81: BRAZIL AD MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 82: ROW AD MARKET FOR DRUG CLASS BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 83: ROW AD MARKET FOR ROUTE OF ADMINISTRATION BY TYPE, MARKET SIZE (2017), FORECAST (2018-2028)

TABLE 84: ROW AD MARKET FOR METHOD OF DISPENSING BY TYPE, MARKET SIZE (2017), AND FORECAST (2018-2028)

TABLE 85: RANKING OF TOP EMERGING COMPANIES BASED ON REGULATORY ALLOWANCES

TABLE 86: REVENUES GAINED THROUGH THE SALE OF MAJOR PRODUCTS IN MILLION \$

TABLE 87: SANOFI'S OWNED PATENTS COVERING DUPIXENT

TABLE 88: SANOFI'S DEVELOPMENT PIPELINE UNDER NEURODEGENERATION

TABLE 89: SANOFI'S DEVELOPMENT PIPELINE UNDER INFLAMMATION AND IMMUNOLOGY

TABLE 90: SANOFI'S DEVELOPMENT PIPELINE UNDER ONCOLOGY

TABLE 91: SANOFI'S DEVELOPMENT PIPELINE UNDER RARE DISEASES

TABLE 92: SANOFI'S DEVELOPMENT PIPELINE UNDER RARE BLOOD DISORDERS

TABLE 93: SANOFI'S DEVELOPMENT PIPELINE UNDER VACCINES

TABLE 94: SANOFI'S RESEARCH AND DEVELOPMENT ACTIVITIES

TABLE 95: SANOFI'S RECENT DEVELOPMENTS

TABLE 96: SANOFI'S ANTICIPATED MILESTONES

TABLE 97: PFIZER TOP 5 PRODUCTS UNDER MAJOR PRODUCTS IN BIOPHARMA SEGMENT

TABLE 98: PFIZER TOP 5 PRODUCTS UNDER MAJOR PRODUCTS IN UPJOHN SEGMENT

TABLE 99: CLINICAL PROGRAMS UNDER INFLAMMATION AND IMMUNOLOGY AREA

TABLE 99: CLINICAL PROGRAMS UNDER INTERNAL MEDICINES

TABLE 100: CLINICAL PROGRAMS UNDER ONCOLOGY THERAPY AREA

TABLE 101: CLINICAL PROGRAMS UNDER RARE DISEASES

TABLE 102: CLINICAL PROGRAMS UNDER VACCINES

TABLE 103: RESEARCH AND DEVELOPMENT ACTIVITIES OF PFIZER

TABLE 104: RECENT DEVELOPMENTS MADE BY PFIZER

TABLE 105: REGENERON'S MAJOR PRODUCTS IN THE U.S MARKET AREA FOR THE FIRST 9 MONTHS OF 2019

TABLE 106: REGENERON'S MAJOR PRODUCTS IN THE U.S AREA(FIRST 9 MONTHS, 2019) COLLABORATED WITH SANOFI

TABLE 107: PATENT INFORMATION WITH RESPECT TO DUPIXENT

TABLE 108: CLINICAL PROGRAMS UNDER IMMUNOLOGY AND INFLAMMATORY DISEASES

TABLE 109: CLINICAL PROGRAMS UNDER ONCOLOGY

TABLE 110: CLINICAL PROGRAMS UNDER CARDIOVASCULAR/METABOLIC DISEASES AND RARE DISEASES

TABLE 111: RESEARCH AND DEVELOPMENT ACTIVITIES OF REGENERON

TABLE 112: RECENT DEVELOPMENTS OF REGENERON

TABLE 113: UNION THERAPEUTICS PRODUCT PIPELINE

TABLE 114: UNION THERAPEUTICS RESEARCH AND DEVELOPMENT ACTIVITIES

TABLE 115: UNION THERAPEUTICS RECENT DEVELOPMENT ACTIVITIES

TABLE 116: UNION THERAPEUTICS PRESENTATIONS

TABLE 117: ANAPTYSBIO PRODUCT PIPELINE

TABLE 118: ANAPTYSBIO ANTICIPATED FUTURE MILESTONES

TABLE 119: ANAPTYSBIO RESEARCH AND DEVELOPMENT ACTIVITIES

TABLE 120: ANAPTYSBIO PRESENTATIONS AND CONFERENCES

TABLE 121: ABEOME PRODUCT PIPELINE

TABLE 122: ABEOME RECENT DEVELOPMENTS

TABLE 123: ABEOME PRESENTATION

TABLE 124: ASANA BIOSCIENCES PRODUCT PIPELINE

TABLE 125: ASANA BIOSCIENCES RESEARCH AND DEVELOPMENT ACTIVITIES

TABLE 126: ASANA BIOSCIENCES ACHIEVED MILESTONES

TABLE 127: ASANA BIOSCIENCES PUBLICATIONS

TABLE 128: ASANA BIOSCIENCES PRESENTATIONS AND CONFERENCES

TABLE 129: SPHERIUM BIOMED PRODUCT PIPELINE

TABLE 130: SPHERIUM BIOMED RESEARCH AND DEVELOPMENT ACTIVITIES

TABLE 131: SPHERIUM BIOMED RECENT DEVELOPMENT ACTIVITIES

TABLE 132: SPHERIUM BIOMED PRESENTATIONS

TABLE 133: DS BIOPHARMA PRODUCT PIPELINE

TABLE 134: DS BIOPHARMA U.S PATENTS

TABLE 135: DS BIOPHARMA RESEARCH AND DEVELOPMENT ACTIVITIES

TABLE 136: DS BIOPHARMA RECENT DEVELOPMENT ACTIVITIES

TABLE 137: DS BIOPHARMA COLLABORATIONS

TABLE 138: DS BIOPHARMA PRESENTATIONS/EVENTS AND CONFERENCES

TABLE 139: RALEXAR THERAPEUTICS U.S PATENTS

TABLE 140: RALEXAR THERAPEUTICS RESEARCH AND DEVELOPMENT ACTIVITIES

TABLE 141: RALEXAR THERAPEUTICS MILESTONE ACHIEVEMENTS

TABLE 142: AKAAL PHARMA PRODUCT PIPELINE

TABLE 143: AKAAL PHARMA U.S PATENTS

TABLE 144: AKAAL PHARMA RESEARCH AND DEVELOPMENT ACTIVITIES

TABLE 145: AKAAL PHARMA RECENT DEVELOPMENT ACTIVITIES

TABLE 146: AKAAL PHARMA PRESENTATION

TABLE 147: AOBIOME PRODUCT PIPELINE

TABLE 148: AOBIOME U.S PATENTS

TABLE 149: AOBIOME RESEARCH AND DEVELOPMENT ACTIVITIES

TABLE 150: AOBIOME RECENT DEVELOPMENT ACTIVITIES

TABLE 151: AOBIOME PRESENTATION

TABLE 152: MENLO THERAPEUTICS PRODUCT PIPELINE

TABLE 153: MENLO THERAPEUTICS U.S PATENTS

TABLE 154: MENLO THERAPEUTICS RESEARCH AND DEVELOPMENT ACTIVITIES

TABLE 155: MENLO THERAPEUTICS RECENT DEVELOPMENT ACTIVITIES

TABLE 156: MENLO THERAPEUTICS PRESENTATIONS

TABLE 157: MENLO THERAPEUTICS MILESTONE ACHIEVED

TABLE 158: BOTANIX PRODUCT PIPELINE

TABLE 159: BOTANIX RESEARCH AND DEVELOPMENTS

TABLE 160: BOTANIX RECENT DEVELOPMENTS

TABLE 161: BOTANIX PRESENTATIONS

TABLE 162: CARA THERAPEUTICS PRODUCT PIPELINE

TABLE 163: CARA THERAPEUTICS RESEARCH AND DEVELOPMENT ACTIVITIES

TABLE 164: CARA THERAPEUTICS RECENT DEVELOPMENT ACTIVITIES

TABLE 165: CARA THERAPEUTICS PRESENTATIONS

TABLE 166: KYMAB PRODUCT PIPELINE

TABLE 167: KYMAB RESEARCH AND DEVELOPMENT ACTIVITIES

TABLE 168: KYMAB RECENT DEVELOPMENT ACTIVITIES

TABLE 169: KYMAB PRESENTATIONS

TABLE 170: KYMAB CONFERENCES

TABLE 171: KYMAB PUBLICATIONS

TABLE 172: MATRISYS PRODUCT PIPELINE

TABLE 173: MATRISYS PUBLICATIONS

TABLE 174: QURIENT PRODUCT PIPELINE

TABLE 175: QURIENT RESEARCH AND DEVELOPMENT ACTIVITIES

TABLE 176: QURIENT RECENT DEVELOPMENT ACTIVITIES

TABLE 177: QURIENT PUBLICATIONS

# List Of Figures, Charts and Diagrams in Global Atopic Dermatitis Therapeutic Market: Opportunities Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analytics, Current Market Size and Market Forecast 2018-2028

## LIST OF FIGURES

FIGURE 01: GLOBAL ATOPIC DERMATITIS MARKET BY GEOGRAPHY 2017 V/S 2028

FIGURE 02: GLOBAL ATOPIC DERMATITIS MARKET 2017-2028: MARKET SNAPSHOT

FIGURE 03: ATOPIC DERMATITIS MARKET BY METHOD OF DISPENSING, 2017

FIGURE 04: ATOPIC DERMATITIS MARKET BY ROA, 2017

FIGURE 05: KEY EVENTS IN ATOPIC DERMATITIS AREA

FIGURE 06: ATOPIC DERMATITIS EPIDEMIOLOGY FORECAST OF US POPULATION (ADULTS), IN MILLION

FIGURE 07: ATOPIC DERMATITIS DEALS, GEOGRAPHY SPLIT-UP

FIGURE 08: ATOPIC DERMATITIS THERAPEUTIC AREA DEALS OVERVIEW

FIGURE 09: ATOPIC DERMATITIS DEALS ANNUAL FREQUENCY, 2011-2019

FIGURE 10: ATOPIC DERMATITIS DRUG PIPELINE, HSD SPLIT

FIGURE 11: ATOPIC DERMATITIS DRUG PIPELINE SPLIT BY GEOGRAPHY

FIGURE 12: ATOPIC DERMATITIS DRUG PIPELINE SPLIT, MAJOR APPROVAL MARKETS

FIGURE 13: ATOPIC DERMATITIS DRUG PIPELINE SPLIT BY ROA

FIGURE 14: TOPICALS BY HSD SPLIT-UP

FIGURE 15: ORALS BY HSD SPLIT-UP

FIGURE 16: PIPELINE ANALYTICS BY INJECTABLES, SPLIT BY TECHNIQUE USED

FIGURE 17: INJECTABLES BY HSD SPLIT-UP

FIGURE 18: ATOPIC DERMATITIS DRUG CLASSES SCENARIO

FIGURE 19: ANTI-INFLAMMATORY DRUGS SPLIT BY HSD

FIGURE 20: JAK INHIBITORS SPLIT BY HSD

FIGURE 21: CORTICOSTEROIDS HOLD MAXIMUM SHARE IN THE ATOPIC DERMATITIS MARKET, 2018

FIGURE 22: GLOBAL CORTICOSTEROIDS MARKET, 2018 V/S 2028

FIGURE 23: GLOBAL EMOLLIENTS/MOISTURIZERS MARKET, 2018 V/S 2028

FIGURE 24: GLOBAL PDE4 INHIBITORS MARKET, 2018 V/S 2028

FIGURE 25: GLOBAL CALCINEURIN INHIBITORS MARKET, 2018 V/S 2028

FIGURE 26: GLOBAL BIOLOGICS MARKET, 2018 V/S 2028

FIGURE 27: OTHER DRUGS MARKET, 2018 V/S 2028

FIGURE 28: TOPICAL ROA IS EXPECTED TO HOLD MAXIMUM SHARE IN THE AD MARKET, 2018

FIGURE 29: GLOBAL ATOPIC DERMATITIS ROA SCENARIO, 2017

FIGURE 30: GLOBAL TOPICAL DRUGS MARKET, 2018 V/S 2028

FIGURE 31: GLOBAL ORALS DRUGS MARKET, 2018 V/S 2028

FIGURE 32: GLOBAL INJECTABLES DRUGS MARKET, 2018 V/S 2028

FIGURE 33: PRESCRIPTION SEGMENT IS EXPECTED TO HOLD MAXIMUM SHARE IN THE AD MARKET, 2018

FIGURE 34: GLOBAL ATOPIC DERMATITIS MARKET BY METHOD OF DISPENSING, 2017

FIGURE 35: GLOBAL PRESCRIPTION MARKET, 2018 V/S 2028

FIGURE 36: GLOBAL OTC MARKET, 2018 V/S 2028

FIGURE 37: GLOBAL ATOPIC DERMATITIS MARKET SPLIT BY 11 MM, 2018 V/S 2028

FIGURE 38: GLOBAL ATOPIC DERMATITIS MARKET SPLIT BY 11 MM, 2018

FIGURE 39: US DRUG CLASS MARKET SPLIT, 2018

FIGURE 40: US ROA MARKET SPLIT, 2018

FIGURE 41: US MARKET FOR METHOD OF DISPENSING, 2018

FIGURE 42: UK DRUG CLASS MARKET SPLIT, 2018

FIGURE 43: UK ROA MARKET SPLIT, 2018 V/S 2028

FIGURE 44: UK MARKET FOR METHOD OF DISPENSING, 2018 V/S 2028

FIGURE 45: GERMANY DRUG CLASS MARKET, 2018 V/S 2028

FIGURE 46: GERMANY ROA MARKET SPLIT, 2028

FIGURE 47: GERMANY MARKET FOR METHOD OF DISPENSING, 2028

FIGURE 48: FRANCE DRUG CLASS MARKET SPLIT, 2018

FIGURE 49: FRANCE ROA MARKET SPLIT, 2018 V/S 2028

FIGURE 50: FRANCE MARKET FOR METHOD OF DISPENSING, 2018 V/S 2028

FIGURE 51: ITALY DRUG CLASS MARKET, 2018 V/S 2028

FIGURE 52: ITALY ROA MARKET SPLIT, 2018

FIGURE 53: ITALY MARKET FOR METHOD OF DISPENSING, 2018 V/S 2028

FIGURE 54: SPAIN DRUG CLASS MARKET SPLIT, 2018

FIGURE 55: SPAIN ROA MARKET SPLIT, 2018 V/S 2028

FIGURE 56: SPAIN MARKET FOR METHOD OF DISPENSING, 2018

FIGURE 57: CHINA DRUG CLASS MARKET SPLIT, 2018 V/S 2028

FIGURE 58: CHINA ROA MARKET SPLIT, 2028

FIGURE 59: CHINA MARKET FOR METHOD OF DISPENSING, 2018 V/S 2028

FIGURE 60: JAPAN DRUG CLASS MARKET SPLIT, 2018

FIGURE 61: JAPAN ROA MARKET SPLIT, 2018 V/S 2028

FIGURE 62: JAPAN MARKET FOR METHOD OF DISPENSING, 2028

FIGURE 63: INDIA DRUG CLASS MARKET SPLIT, 2018 V/S 2028

FIGURE 64: INDIA ROA MARKET SPLIT, 2018 V/S 2028

FIGURE 65: INDIA MARKET FOR METHOD OF DISPENSING, 2028 V/S 2028

FIGURE 66: RUSSIA DRUG CLASS MARKET SPLIT, 2028

FIGURE 67: RUSSIA ROA MARKET SPLIT, 2028

FIGURE 68: RUSSIA MARKET FOR METHOD OF DISPENSING, 2028

FIGURE 69: BRAZIL DRUG CLASS MARKET SPLIT, 2018 V/S 2028

FIGURE 70: BRAZIL ROA MARKET SPLIT, 2018 V/S 2028

FIGURE 71: BRAZIL MARKET FOR METHOD OF DISPENSING, 2018 V/S 2028

FIGURE 72: COMPARISON OF TOP FOUR COMPANIES BASED ON R&D INVESTMENTS IN MILLION \$

FIGURE 73: PIPELINE PORTFOLIO WITH NUMBER OF MOLECULES

FIGURE 74: EXPECTED MARKET ENTRY IN THE U.S IRRESPECTIVE OF ATOPIC DERMATITIS MARKET

FIGURE 75: EXPECTED MARKET ENTRY IN THE U.S WITH RESPECT TO ATOPIC DERMATITIS MARKET

FIGURE 76: PATENT PORTFOLIO COMPARISON OF TOP 10 EMERGING COMPANIES

FIGURE 77: TIME LINE OF PATENT EXPIRIES IRRESPECTIVE OF ATOPIC DERMATITIS MARKET

FIGURE 78: TIME LINE OF PATENT EXPIRIES WITH RESPECT TO ATOPIC DERMATITIS

FIGURE 79: RANKING TOP 10 EMERGING COMPANIES BASED ON THEIR PARTNERING ACTIVITIES

FIGURE 80: COMPARISON PIE CHARTS FOR INCOME GAINED THROUGH SALES IN 2018 AND 2019

FIGURE 81: FINANCIAL INFORMATION OF PFIZER FOR 2016, 2017 AND 2018

FIGURE 82: REVENUE BREAKDOWN BETWEEN PFIZER'S SEGMENTS FOR THE FIRST NINE MONTHS ENDED IN 2019

FIGURE 83: FINANCIAL INFORMATION OF REGENERON FOR 2016, 2017 AND 2018

FIGURE 84: TOTAL REVENUE BREAKDOWN FOR THE FIRST NINE MONTHS OF 2019

FIGURE 85: NET LOSS FOR THE YEAR ENDED DECEMBER 31, 2017-18 (THOUSAND DOLLAR)

FIGURE 86: RESEARCH AND DEVELOPMENT EXPENSES FOR THE YEAR ENDED DECEMBER 31, 2017-18

FIGURE 87: NET LOSS FOR THE YEAR ENDED DECEMBER 31, 2018, 2017, 2016



# How to Buy...

Global Atopic Dermatitis Therapeutic Market: Opportunities Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analytics, Current Market Size and Market Forecast 2018-2028

## Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/270537>

## Option 2 - Request a Proforma Invoice

Fill in the details below, and **Scan** this page **and email** it to us at [bioportfolio97@gmail.com](mailto:bioportfolio97@gmail.com) We will send you a Proforma Invoice and deliver your report on settlement.

**Your Name:** .....

**Job Title:** .....

**Your Email:** .....

**Your Contact Phone:** .....

**Company Name:** .....

**Address:** .....

**Post/Zip Code:** .....

**Country:** .....

**P.O. Number:** .....

**Any Other Instructions:** .....

**Pricing Options:** (please tick one)

- \$1063** | Single User Price
- \$1530** | Site License Price
- \$2125** | Global License Price

**Payment Options:** (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:** .....

## Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.